Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 3992 Bluebonnet Dr, Building 14 STAFFORD TX 77477 |
Tel: | N/A |
Website: | https://greenwichlifesciences.com |
IR: | See website |
Key People | ||
Snehal Patel Chief Executive Officer, Chief Financial Officer, Director | Jaye Thompson Vice President - Clinical & Regulatory Affairs | F. Joseph Daugherty Chief Medical Officer, Director |
Business Overview |
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of GP2, immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2)/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. GP2 will be delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. The Company's Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver certain immune system components to inhibit the spread of cancer. |
Financial Overview |
For the fiscal year ended 31 December 2023, Greenwich Lifesciences Inc revenues was not reported. Net loss increased 14% to $8.9M. Higher net loss reflects Research and development increase of 19% to $7.7M (expense), General and administrative increase of 4% to $1.6M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.61 to -$0.69. |
Employees: | 3 as of Apr 10, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $158.62M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$9.32M as of Dec 31, 2023 |
Net annual income (TTM): | -$8.89M as of Dec 31, 2023 |
Free cash flow (TTM): | -$6.48M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 12,878,409 as of Apr 10, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |